Paradigm shift in the management of metabolic diseases - next generation incretin therapy.

Recently impressive weight loss has been reported for novel incretin therapies based on dual and triple hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases where weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases and non-alcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.